 | • レポートコード：MRC2303L232 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に981.34百万ドルであった世界のプレガバリン市場規模が2022年に1,050.75百万ドルとなり、2027年までに年平均7.32％拡大して1,500.01百万ドルに達すると予測されています。本書では、プレガバリンの世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、剤形別（持続放出性薬剤、経口カプセル、内服液、経口錠剤）分析、薬剤分類別（抗けいれん薬、線維筋痛薬）分析、用途別（不安障害、てんかん、神経因性疼痛）分析、エンドユーザー別（在宅医療、病院、研究機関、専門クリニック）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、Almelo Private Limited、Amneal Pharmaceuticals LLC、Aurobindo Pharma Limited、Bal Pharma Limited、Biomax Biotechnics Private Limited、Changzhou Pharmaceutical Factory、Cipla Limited、Dongbang FTL、Genesis Biotec Inc.、Glenmark Pharmaceuticals Ltd.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のプレガバリン市場規模：剤形別 - 持続放出性薬剤の市場規模 - 経口カプセルの市場規模 - 内服液の市場規模 - 経口錠剤の市場規模 ・世界のプレガバリン市場規模：薬剤分類別 - 抗けいれん薬の市場規模 - 線維筋痛薬の市場規模 ・世界のプレガバリン市場規模：用途別 - 不安障害における市場規模 - てんかんにおける市場規模 - 神経因性疼痛における市場規模 ・世界のプレガバリン市場規模：エンドユーザー別 - 在宅医療における市場規模 - 病院における市場規模 - 研究機関における市場規模 - 専門クリニックにおける市場規模 ・世界のプレガバリン市場規模：地域別 - 南北アメリカのプレガバリン市場規模 アメリカのプレガバリン市場規模 カナダのプレガバリン市場規模 ブラジルのプレガバリン市場規模 ... - アジア太平洋のプレガバリン市場規模 日本のプレガバリン市場規模 中国のプレガバリン市場規模 インドのプレガバリン市場規模 韓国のプレガバリン市場規模 台湾のプレガバリン市場規模 ... - ヨーロッパ/中東/アフリカのプレガバリン市場規模 イギリスのプレガバリン市場規模 ドイツのプレガバリン市場規模 フランスのプレガバリン市場規模 ロシアのプレガバリン市場規模 ... - その他地域のプレガバリン市場規模 ・競争状況 ・企業情報 |
The Global Pregabalin Market size was estimated at USD 981.34 million in 2021 and expected to reach USD 1,050.75 million in 2022, and is projected to grow at a CAGR 7.32% to reach USD 1,500.01 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Pregabalin to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Dosage Forms, the market was studied across Extended Release, Oral Capsule, Oral Solution, and Oral Tablet.
Based on Drug Class, the market was studied across Anticonvulsants and Fibromyalgia Agents.
Based on Application, the market was studied across Anxiety Disorder, Epilepsy, and Neuropathic Pain.
Based on End-Users, the market was studied across Homecare, Hospitals, Research institute, and Specialty Clinics.
Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pregabalin market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pregabalin Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pregabalin Market, including Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Bal Pharma Limited, Biomax Biotechnics Private Limited, Changzhou Pharmaceutical Factory, Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Glenmark Pharmaceuticals Ltd., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., ZCL Chemicals Ltd., and Zydus Group.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pregabalin Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pregabalin Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pregabalin Market?
4. What is the competitive strategic window for opportunities in the Global Pregabalin Market?
5. What are the technology trends and regulatory frameworks in the Global Pregabalin Market?
6. What is the market share of the leading vendors in the Global Pregabalin Market?
7. What modes and strategic moves are considered suitable for entering the Global Pregabalin Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing cases of epilepsy and anxiety disorders
5.1.1.2. Favorable government initiatives for raising awareness for anxiety issues
5.1.1.3. Rising geriartic population with neuropathic pain
5.1.2. Restraints
5.1.2.1. Presence of substitutes and lack of awareness
5.1.3. Opportunities
5.1.3.1. Rising approvals of generic versions of the medicine
5.1.3.2. Advancements and product enhancements for pregabalin
5.1.4. Challenges
5.1.4.1. Adverse effects on health and product recalls
5.2. Cumulative Impact of COVID-19
6. Pregabalin Market, by Dosage Forms
6.1. Introduction
6.2. Extended Release
6.3. Oral Capsule
6.4. Oral Solution
6.5. Oral Tablet
7. Pregabalin Market, by Drug Class
7.1. Introduction
7.2. Anticonvulsants
7.3. Fibromyalgia Agents
8. Pregabalin Market, by Application
8.1. Introduction
8.2. Anxiety Disorder
8.3. Epilepsy
8.4. Neuropathic Pain
9. Pregabalin Market, by End-Users
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Research institute
9.5. Specialty Clinics
10. Pregabalin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Pregabalin Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Pregabalin Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Pregabalin Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Almelo Private Limited
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Amneal Pharmaceuticals LLC
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Aurobindo Pharma Limited
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bal Pharma Limited
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Biomax Biotechnics Private Limited
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Changzhou Pharmaceutical Factory
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Cipla Limited
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Dongbang FTL
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Genesis Biotec Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Glenmark Pharmaceuticals Ltd.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Hikal Ltd.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Lupin Limited
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Medley Pharmaceuticals Limited
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Novartis AG
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Pfizer Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Teva Pharmaceutical Industries Ltd.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Torrent Pharmaceuticals Ltd.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Viatris Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. ZCL Chemicals Ltd.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Zydus Group
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
